公开(公告)号：JP2004091344A

公开(公告)日：2004-03-25

申请号：JP2002252180

申请日：2002-08-29

申请人： Torao Ishida ,  Suzuka Univ Of Medical Science ,  学校法人鈴鹿医療科学大学 ,  石田 寅夫

发明人： ISHIDA TORAO ,  ZHANG YANJUN ,  KONDO HIROYO ,  O SHIHO

IPC分类号： C12Q1/02 ,  A61K31/00 ,  A61K31/22 ,  A61K31/351 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/47 ,  A61K35/28 ,  A61K35/30 ,  A61K45/00 ,  A61L27/00 ,  A61P25/00 ,  A61P43/00 ,  C12N5/0793 ,  G01N33/50 ,  C12N5/06

CPC分类号： G01N33/5073 ,  A61K31/00 ,  A61K31/22 ,  A61K31/351 ,  A61K31/366 ,  A61K31/404 ,  A61K31/47 ,  C12N5/0619 ,  C12N2506/1353 ,  G01N33/5008 ,  G01N33/5017 ,  G01N33/5058

摘要： PROBLEM TO BE SOLVED: To obtain a composition for differentiating and maturing a neurocyte, to provide a method therefor, the neurocyte obtained by the method and a method for search for the composition. SOLUTION: The composition differentiates the non-neurocyte into the neurocyte and/or matures the non-neurocyte into the neurocyte and/or thereby treats neuropathic diseases or suppresses the malignant alteration thereof. The composition comprises a low-molecular substance having the ability to differentiate the non-neurocyte into the neurocyte without treating the non-neurocyte with a cell division inducer and/or mature the neurocyte without treating the neurocyte with the cell division inducer and having merely the toxicity within a pharmaceutical tolerance as an active ingredient. The method for differentiating the non-neurocyte into the neurocyte comprises bringing the composition, as necessary after activation, into contact with the non-neurocyte and differentiating the non-neurocyte into the neurocyte without treating the non-neurocyte with the cell division inducer. The neurocyte is obtained by the method. The method for search for the composition comprises bringing the low-molecular substance having merely the toxicity within the pharmaceutical tolerance, as necessary after activation, into contact with the non-neurocyte or neurocyte without being treated with the cell division inducer and examining the presence or absence of differentiation of the non-neurocyte into the neurocyte and/or maturation of the neurocyte. COPYRIGHT: (C)2004,JPO

公开(公告)号：JP2006213611A

公开(公告)日：2006-08-17

申请号：JP2005025806

申请日：2005-02-02

申请人： Torao Ishida ,  Suzuka Univ Of Medical Science ,  学校法人鈴鹿医療科学大学 ,  寅夫 石田

发明人： ISHIDA TORAO ,  KO AKIRA ,  ZHU XUXIANG

IPC分类号： A61K31/196 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00 ,  C07C229/48

CPC分类号： C07C229/48 ,  C07C2601/02

摘要： PROBLEM TO BE SOLVED: To provide a new preventive or therapeutic agent for stroke or sequelae of stroke. SOLUTION: The preventive or therapeutic agent for stroke or sequelae of stroke contains a compound selected from 1-aminocyclopropane carboxylic acid, its prodrug and pharmaceutically permissible salts and hydrates of those as a main ingredient. For example, 1-aminocyclopropane carboxylic acid hydrochloride-hydrate suppresses 90% onset of stroke in 50 mg/kg dose which corresponds to ≤1/100 acute toxicity. In the case of onset of stroke, the sequelae are slight. COPYRIGHT: (C)2006,JPO&NCIPI

摘要翻译： 要解决的问题：为中风或中风后遗症提供新的预防或治疗剂。 解决方案：中风或中风后遗症的预防或治疗剂含有选自1-氨基环丙烷羧酸，其前药和药学上允许的盐和作为主要成分的水合物的化合物。 例如，1-氨基环丙烷羧酸盐酸盐水合物以50mg / kg剂量抑制90％的中风发作，相当于≤1/ 100急性毒性。 在中风发作的情况下，后遗症是轻微的。 版权所有（C）2006，JPO＆NCIPI

公开(公告)号：JP2006151835A

公开(公告)日：2006-06-15

申请号：JP2004341367

申请日：2004-11-26

申请人： Torao Ishida ,  Suzuka Univ Of Medical Science ,  学校法人鈴鹿医療科学大学 ,  寅夫 石田

发明人： ISHIDA TORAO ,  KAKU RIHEI

IPC分类号： A61K31/34 ,  A61K31/216 ,  A61K31/335 ,  A61K31/357 ,  A61P25/00 ,  A61P43/00 ,  C07D307/80 ,  C07D307/84 ,  C07D313/06 ,  C07D313/14 ,  C07D319/20 ,  C12N5/07 ,  C12N5/074 ,  C12N5/0789 ,  C12N5/0797

摘要： PROBLEM TO BE SOLVED: To provide a new agent for the treatment of diseases caused by nerve cell degeneration, etc., its active component, a method for the preparation of the active component, and a substance and technique necessary for the method. SOLUTION: It has been found that a compound selected from salvianolic acid B, its optical or geometrical isomer having an action similar to salvianolic acid B, their prodrugs, pharmacologically permissible salt and hydrate of the above compounds and their prodrugs has an action to effect the proliferation and/or differentiation of a neural stem cell while protecting the neural stem cell or its differentiated cell. The finding induces the development of an agent acting on the neural cell and containing these substances as active components, a method for acting on the neural cell by using the acting agent, a method for the preparation of liquid containing neural cell and produced by using the acting method, a liquid containing neural cell and produced by using the preparation method, and an agent for the treatment of diseases caused e.g. by neural cell degeneration by using the acting agent and/or the liquid containing the neural cell as active components. COPYRIGHT: (C)2006,JPO&NCIPI

摘要翻译： 待解决的问题：为了提供治疗由神经细胞变性等引起的疾病的新药，其活性成分，制备活性成分的方法以及该方法所需的物质和技术 。 解决方案：已经发现，选自salvianolic acid B，其光学或几何异构体具有类似于salvianolic acid B的作用，其前药，药理学上允许的盐和上述化合物及其前药的水合物的化合物具有作用 以在保护神经干细胞或其分化的细胞的同时实现神经干细胞的增殖和/或分化。 该发现诱导了作用于神经细胞并且含有这些物质作为活性成分的药剂的开发，通过使用作用剂作用于​​神经细胞的方法，制备含神经细胞的液体的方法，并通过使用 作用方法，含有神经细胞的液体并通过使用制备方法制备，以及用于治疗引起的疾病的试剂 通过使用作用剂和/或含有神经细胞的液体作为活性成分的神经细胞变性。 版权所有（C）2006，JPO＆NCIPI

公开(公告)号：JP2008214198A

公开(公告)日：2008-09-18

申请号：JP2007049712

申请日：2007-02-28

申请人： Torao Ishida ,  Suzuka Univ Of Medical Science ,  学校法人鈴鹿医療科学大学 ,  寅夫 石田

发明人： ISHIDA TORAO ,  O TAKESHI ,  MIURA TOSHIHIRO

IPC分类号： A61K36/00 ,  A23L1/30 ,  A61P3/06 ,  A61P3/08 ,  A61P9/12

摘要： PROBLEM TO BE SOLVED: To provide a medicine composition and a health food for preventing or treating hypertension, hyperlipemia, and diabetes. SOLUTION: The present invention relates to a composition containing the raw or dried product or extract of Morus plants, Lotus plants, Crataegus plants, and Salvia plants, and to a medicine composition and a health food for preventing or treating hypertension, hyperlipemia, and diabetes. The composition, the medicine composition and the health food control the elevations of blood pressure, total plasma cholesterol concentration, triglyceride concentration, and blood glucose level, and prevents or treats the hypertension, hyperlipemia, and diabetes. COPYRIGHT: (C)2008,JPO&INPIT

摘要翻译： 待解决的问题：提供用于预防或治疗高血压，高脂血症和糖尿病的药物组合物和保健食品。 解决方案：本发明涉及含有桑兰植物，莲花植物，山楂植物和丹参植物的生或干产物或提取物的组合物，以及用于预防或治疗高血压，高脂血症的药物组合物和保健食品 ，和糖尿病。 组合物，药物组合物和保健食品控制血压升高，总血浆胆固醇浓度，甘油三酯浓度和血糖水平，并预防或治疗高血压，高脂血症和糖尿病。 版权所有（C）2008，JPO＆INPIT

公开(公告)号：JP2006232698A

公开(公告)日：2006-09-07

申请号：JP2005047343

申请日：2005-02-23

申请人： Torao Ishida ,  Suzuka Univ Of Medical Science ,  学校法人鈴鹿医療科学大学 ,  寅夫 石田

发明人： ISHIDA TORAO ,  KO AKIRA

IPC分类号： A61K31/222 ,  A61P9/00 ,  A61P9/02 ,  A61P25/28

CPC分类号： A61K31/222

摘要： PROBLEM TO BE SOLVED: To provide a new preventing or treating medicine of cerebral stroke or the late sequela of the stroke. SOLUTION: This preventing or treating medicine is provided by containing salvianolic acid B, its prodrug, their pharmaceutically acceptable salts or hydrates as main components. For example, the salvianolic acid B suppresses the onset of the cerebral stroke by 30 % by the administration of once daily, 5 times a week and 22.5 mg/kg per one time, and even having the onset of the cerebral stroke, the late sequela is moderate. COPYRIGHT: (C)2006,JPO&NCIPI

摘要翻译： 要解决的问题：提供一种新的预防或治疗脑卒中或中风后期的药物。 解决方案：该预防或治疗药物通过含有salvianolic acid B，其前药，其药学上可接受的盐或水合物作为主要成分来提供。 例如，丹酚酸B通过每天施用一次，每周5次，每次施用22.5mg / kg，甚至发生脑中风，晚期后遗症，将脑中风的发作抑制30％ 温和 版权所有（C）2006，JPO＆NCIPI

公开(公告)号：JP2006076948A

公开(公告)日：2006-03-23

申请号：JP2004264016

申请日：2004-09-10

申请人： Torao Ishida ,  Suzuka Univ Of Medical Science ,  学校法人鈴鹿医療科学大学 ,  寅夫 石田

发明人： ISHIDA TORAO ,  KAKU RIHEI

IPC分类号： A61K31/343 ,  A61K45/00 ,  A61P9/00 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P25/32 ,  A61P43/00 ,  C07D307/86 ,  C12N5/07 ,  C12N5/074 ,  C12N5/0789 ,  C12N5/0797

摘要： PROBLEM TO BE SOLVED: To obtain a nerve trunk cell proliferation agent, to provide a method for proliferating a nerve trunk cell using the proliferation agent, to provide a nerve trunk cell-containing liquid proliferated by the method, and to provide a therapeutic agent for a neurological disease containing the nerve trunk cell-containing liquid or the proliferation agent as an active ingredient. SOLUTION: This nerve trunk cell proliferation agent contains a compound selected from salvianolic acid B, an optical or geometrical isomer thereof having nerve trunk cell proliferation action similar to that of the salvianolic acid B, a prodrug thereof, a pharmaceutically acceptable salt of the compound or the prodrug, and a hydrate thereof as an active ingredient, wherein the compound has the nerve trunk cell proliferation action and the action is imparted to the proliferation agent. The method for proliferating the nerve trunk cell uses the proliferation agent. The nerve trunk cell-containing liquid is obtained by the method. The therapeutic agent for the neurological disease contains the cell-containing liquid as the active ingredient. Further, the therapeutic agent for the neurological disease contains the proliferation agent as the active ingredient and is based on a mechanism of the nerve trunk cell proliferation action. COPYRIGHT: (C)2006,JPO&NCIPI

摘要翻译： 待解决的问题为了获得神经干细胞增殖剂，提供使用增殖剂增殖神经干细胞的方法，以提供通过该方法增殖的含神经干细胞的液体，并提供一种 用于含神经干细胞的液体或增殖剂作为活性成分的神经疾病的治疗剂。 解决方案：该神经干细胞增殖剂含有选自丹参酸B，其光学或几何异构体的化合物，其具有与丹酚酸B类似的神经干细胞增殖作用，其前药，药学上可接受的盐 化合物或其前体药物及其水合物作为活性成分，其中所述化合物具有神经干细胞增殖作用，并且赋予增殖剂的作用。 增殖神经干细胞的方法使用增殖剂。 通过该方法获得含神经干细胞的液体。 用于神经疾病的治疗剂含有含细胞的液体作为活性成分。 此外，神经系统疾病的治疗剂含有增殖剂作为活性成分，并且是基于神经干细胞增殖作用的机制。 版权所有（C）2006，JPO＆NCIPI

公开(公告)号：JP2008094767A

公开(公告)日：2008-04-24

申请号：JP2006279309

申请日：2006-10-12

申请人： Torao Ishida ,  Suzuka Univ Of Medical Science ,  学校法人鈴鹿医療科学大学 ,  寅夫 石田

发明人： ISHIDA TORAO ,  XU QIANG

IPC分类号： A61K31/7048 ,  A61P25/00 ,  C12N15/09

摘要： PROBLEM TO BE SOLVED: To provide a new migration promoter to an injured site of a neuronal precursor cell, and an expression promoter of a migration-promoting factor gene of astrocyte. SOLUTION: The migration promoter and the expression promoter of the migration-promoting factor gene contain a compound selected from baicalin, a pharmaceutically acceptable salt thereof, and hydrates thereof as a main component. The baicalin or the like increases the migration to the astrocyte of the neuronal precursor cell so as to be 1.5 times (p=0.012) more than that of a control group, and the migration of NPC so as to be 2.5 times more than the control group. Further, the baicalin or the like increases the mRNA of VEGF so as to be 2.7 times and the mRNA of MCP-1 so as to be 8.2 times more than those of the control group. COPYRIGHT: (C)2008,JPO&INPIT

摘要翻译： 要解决的问题：为神经元前体细胞的受损部位提供新的迁移启动子，以及星形胶质细胞迁移促进因子基因的表达启动子。 解决方案：迁移促进因子基因的迁移启动子和表达启动子含有选自黄芩苷，其药学上可接受的盐及其水合物作为主要成分的化合物。 黄芩苷等增加了神经元前体细胞的星形胶质细胞的迁移，比对照组增加了1.5倍（p = 0.012），NPC的迁移比对照组的2.5倍 组。 此外，黄芩苷等增加了VEGF的mRNA，为MCP-1的mRNA的2.7倍，为对照组的8.2倍。 版权所有（C）2008，JPO＆INPIT